{"generic":"Foscarnet Sodium","drugs":["Foscarnet Sodium","Foscavir"],"mono":{"0":{"id":"54kgs0","title":"Generic Names","mono":"Foscarnet Sodium"},"1":{"id":"54kgs1","title":"Dosing and Indications","sub":[{"id":"54kgs1b4","title":"Adult Dosing","mono":"<ul><li>Correct clinical dehydration prior to initiation of therapy; give all patients 750 to 1000 mL of NS or D5W prior to the first infusion. Administer hydration fluid concurrently with subsequent doses. With doses of 90 to 120 mg\/kg, give 750 to 1000 mL of hydration fluid; with doses of 40 to 60 mg\/kg, give 500 mL of hydration fluid. Decrease hydration fluid volume if clinically indicated. Oral rehydration with similar regimens may be used.<\/li><li><b>AIDS - Cytomegaloviral retinitis:<\/b> induction, 90 mg\/kg IV over 1.5 to 2 hours, every 12 hours OR 60 mg\/kg IV over 1 hour, every 8 hours, for 2 to 3 weeks; then maintenance, 90 to 120 mg\/kg IV over 2 hours, every 24 hours<\/li><li><b>Herpes simplex, Mucocutaneous, acyclovir-resistant - Patient immunocompromised:<\/b> (HIV-infected) 80 to 120 mg\/kg\/day IV in 2 to 3 divided doses until clinical response (guideline dosing)<\/li><li><b>Herpes simplex, Mucocutaneous, acyclovir-resistant - Patient immunocompromised:<\/b> 40 mg\/kg IV, over 1 hr, every 8 to 12 hours for 2 to 3 weeks or until healed (manufacturer dosing)<\/li><li><b>HIV infection - Varicella-zoster virus infection:<\/b> (acyclovir-resistant disease) 90 mg\/kg IV every 12 hours<\/li><\/ul>"},{"id":"54kgs1b5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy in pediatric patients have not been established<\/li><li><b>AIDS - Cytomegaloviral retinitis:<\/b> induction, 60 mg\/kg IV every 8 hours for 14 to 21 days, then 90 to 120 mg\/kg IV once daily for chronic maintenance therapy; for sight-threatening disease, may add ganciclovir 5 to 7.5 mg\/kg IV every 12 hours during induction<\/li><li><b>Cytomegalovirus infection - HIV infection:<\/b> (disseminated disease) induction, 60 mg\/kg IV every 8 hours for 14 to 21 days, then 90 to 120 mg\/kg IV once daily for chronic maintenance therapy <\/li><li><b>Cytomegalovirus infection - HIV infection:<\/b> (CNS disease) 60 mg\/kg IV every 8 hours PLUS ganciclovir 5 mg\/kg IV every 12 hours until symptoms improve, followed by chronic maintenance therapy <\/li><li><b>Herpes simplex, Mucocutaneous, acyclovir-resistant - Patient immunocompromised:<\/b> (HIV-infected) 40 mg\/kg IV 3 times daily OR 60 mg\/kg IV twice daily<\/li><li><b>HIV infection - Varicella-zoster virus infection:<\/b> (acyclovir-resistant disease) 40 to 60 mg\/kg IV (over 2 hours) 3 times daily for 7 to 10 days or until no new lesions appear for 48 hours<\/li><\/ul>"},{"id":"54kgs1b6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> Use modified Cockroft and Gault equation to calculate CrCl; mL\/min\/kg=(140 - age)\/serum creatinine x 72 (females, multiply result by 0.85)<\/li><li><b>Renal impairment, herpes simplex infection, usual dose 40 mg\/kg every 12 hours:<\/b> CrCl greater than 1.4 mL\/min\/kg, give usual dose; CrCl greater than 1 to 1.4 mL\/min\/kg, 30 mg\/kg every 12 hours; CrCl greater than 0.8 to 1 mL\/min\/kg, 20 mg\/kg every 12 hours; CrCl greater than 0.6 to 0.8 mL\/min\/kg, 35 mg\/kg every 24 hours; CrCl greater than 0.5 to 0.6 mL\/min\/kg, 25 mg\/kg every 24 hours; CrCl greater than or equal to 0.4 to 0.5 mL\/min\/kg, 20 mg\/kg every 24 hours; CrCl less than 0.4 mL\/min\/kg, not recommended<\/li><li><b>Renal impairment, herpes simplex infection, usual dose 40 mg\/kg every 8 hours:<\/b> CrCl greater than 1.4 mL\/min\/kg, give usual dose; CrCl greater than 1 to 1.4 mL\/min\/kg, 30 mg\/kg every 8 hours; CrCl greater than 0.8 to 1 mL\/min\/kg, 35 mg\/kg every 12 hours; CrCl greater than 0.6 to 0.8 mL\/min\/kg, 25 mg\/kg every 12 hours; CrCl greater than 0.5 to 0.6 mL\/min\/kg, 40 mg\/kg every 24 hours; CrCl greater than or equal to 0.4 to 0.5 mL\/min\/kg, 35 mg\/kg every 24 hours; CrCl less than 0.4 mL\/min\/kg, not recommended<\/li><li><b>Renal impairment, CMV retinitis induction, usual dose 60 mg\/kg every 8 hours:<\/b> CrCl greater than 1.4 mL\/min\/kg, give usual dose; CrCl greater than 1 to 1.4 mL\/min\/kg, 45 mg\/kg every 8 hours; CrCl greater than 0.8 to 1 mL\/min\/kg, 50 mg\/kg every 12 hours; CrCl greater than 0.6 to 0.8 mL\/min\/kg, 40 mg\/kg every 12 hours; CrCl greater than 0.5 to 0.6 mL\/min\/kg, 60 mg\/kg every 24 hours; CrCl greater than or equal to 0.4 to 0.5 mL\/min\/kg, 50 mg\/kg every 24 hours; CrCl less than 0.4 mL\/min\/kg, not recommended<\/li><li><b>Renal impairment, CMV retinitis induction, usual dose 90 mg\/kg every 12 hours:<\/b> CrCl greater than 1.4 mL\/min\/kg, give usual dose; CrCl greater than 1 to 1.4 mL\/min\/kg, 70 mg\/kg every 12 hours; CrCl greater than 0.8 to 1 mL\/min\/kg, 50 mg\/kg every 12 hours; CrCl greater than 0.6 to 0.8 mL\/min\/kg, 80 mg\/kg every 24 hours; CrCl greater than 0.5 to 0.6 mL\/min\/kg, 60 mg\/kg every 24 hours; CrCl greater than or equal to 0.4 to 0.5 mL\/min\/kg, 50 mg\/kg every 24 hours; CrCl less than 0.4 mL\/min\/kg, not recommended<\/li><li><b>Renal impairment, CMV retinitis maintenance, usual dose 90 mg\/kg every 24 hours:<\/b> CrCl greater than 1.4 mL\/min\/kg, give usual dose; CrCl greater than 1 to 1.4 mL\/min\/kg, 70 mg\/kg every 24 hours; CrCl greater than 0.8 to 1 mL\/min\/kg, 50 mg\/kg every 24 hours; CrCl greater than 0.6 to 0.8 mL\/min\/kg, 80 mg\/kg every 48 hours; CrCl greater than 0.5 to 0.6 mL\/min\/kg, 60 mg\/kg every 48 hours; CrCl greater than or equal to 0.4 to 0.5 mL\/min\/kg, 50 mg\/kg every 48 hours; CrCl less than 0.4 mL\/min\/kg, not recommended<\/li><li><b>Renal impairment, CMV retinitis maintenance, usual dose 120 mg\/kg every 24 hours:<\/b> CrCl greater than 1.4 mL\/min\/kg, give usual dose; CrCl greater than 1 to 1.4 mL\/min\/kg, 90 mg\/kg every 24 hours; CrCl greater than 0.8 to 1 mL\/min\/kg, 65 mg\/kg every 24 hours; CrCl greater than 0.6 to 0.8 mL\/min\/kg, 105 mg\/kg every 48 hours; CrCl greater than 0.5 to 0.6 mL\/min\/kg, 80 mg\/kg every 48 hours; CrCl greater than or equal to 0.4 to 0.5 mL\/min\/kg, 65 mg\/kg every 48 hours; CrCl less than 0.4 mL\/min\/kg, not recommended<\/li><li><b>Hemodialysis:<\/b> Use not recommended; dosage guidelines not established<\/li><\/ul>"},{"id":"54kgs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>AIDS - Cytomegaloviral retinitis<\/li><li>Herpes simplex, Mucocutaneous, acyclovir-resistant - Patient immunocompromised<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>AIDS, Intravitreal - Cytomegaloviral retinitis<\/li><li>Cytomegaloviral pneumonia<\/li><li>Cytomegalovirus infection - HIV infection<\/li><li>Herpes simplex keratitis<\/li><li>HIV infection - Varicella-zoster virus infection<\/li><\/ul>"}]},"2":{"id":"54kgs2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>The major toxicity of foscarnet sodium is renal impairment; therefore, frequent monitoring of serum creatinine, dose adjustment after renal function changes, and adequate hydration is necessary. Seizures related to plasma minerals and electrolyte alterations may occur. Monitor for changes and use mineral and electrolyte supplementation if necessary. Foscarnet sodium should only be used in immunocompromised patients with cytomegalovirus retinitis and mucocutaneous acyclovir-resistant herpes simplex virus infections.<br\/>"},"3":{"id":"54kgs3","title":"Contraindications\/Warnings","sub":[{"id":"54kgs3b9","title":"Contraindications","mono":"Hypersensitivity to foscarnet sodium <br\/>"},{"id":"54kgs3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Renal impairment is the major toxicity; monitoring recommended; dose adjustment based on serum creatinine is necessary and adequate hydration is recommended<\/li><li>-- Seizures, some cases fatal, have been reported; increased risk with impaired baseline renal function, low total serum calcium, and underlying CNS conditions; monitor for electrolyte changes and supplement if necessary<\/li><li>-- Only for use in immunocompromised patients with cytomegalovirus retinitis and mucocutaneous acyclovir-resistant herpes simplex virus infections<\/li><li>Endocrine and Metabolic:<\/li><li>-- Serum electrolyte changes including hypocalcemia, hypophosphatemia, hyperphosphatemia, hypomagnesemia, hypokalemia, and decreased ionized serum calcium have been reported; monitoring and management prior to treatment recommended; decreasing the infusion rate may prevent symptoms; to prevent rapid IV infusion, an infusion pump must be used for administration<\/li><li>-- Use caution in patients with altered calcium or other electrolyte levels before treatment, especially those with neurologic or cardiac abnormalities and those receiving other drugs known to influence minerals and electrolytes<\/li><li>-- Avoid use in patients not able to tolerate a large amount of sodium or water (eg, patients with cardiomyopathy or who are on a controlled sodium diet)<\/li><li>Hematologic:<\/li><li>-- Anemia and granulocytopenia has been reported<\/li><li>Reproductive:<\/li><li>-- Local genital irritation and ulcerations have been reported; adequate hydration and personal hygiene may reduce or prevent this risk<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant use with other potentially nephrotoxic drugs, unless the possible benefit outweighs the potential risks<\/li><\/ul>"},{"id":"54kgs3b11","title":"Pregnancy Category","mono":"<ul><li>Foscarnet: C (FDA)<\/li><li>Foscarnet: B3 (AUS)<\/li><\/ul>"},{"id":"54kgs3b12","title":"Breast Feeding","mono":"Foscarnet: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"54kgs4","title":"Drug Interactions","sub":[{"id":"54kgs4b13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"54kgs4b14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Acyclovir (theoretical)<\/li><li>Ajmaline (theoretical)<\/li><li>Amikacin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Amphotericin B (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Bumetanide (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Capreomycin (theoretical)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cidofovir (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibekacin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Encainide (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Ethacrynic Acid (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Framycetin (theoretical)<\/li><li>Furosemide (theoretical)<\/li><li>Gemifloxacin (probable)<\/li><li>Gentamicin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Isepamicin (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Kanamycin (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methotrexate (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Neomycin (theoretical)<\/li><li>Netilmicin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paromomycin (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (probable)<\/li><li>Pirmenol (theoretical)<\/li><li>Prajmaline (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sisomicin (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spectinomycin (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Streptomycin (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tobramycin (theoretical)<\/li><li>Torsemide (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"}]},"5":{"id":"54kgs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (30%), Nausea (47%), Vomiting (26%)<\/li><li><b>Hematologic:<\/b>Anemia (33%), Granulocytopenic disorder (17%)<\/li><li><b>Neurologic:<\/b>Headache (26%)<\/li><li><b>Other:<\/b>Fever (5% or more)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Hyperphosphatemia (6%), Hypocalcemia (15% to 30%), Hypokalemia (16% to 48%), Hypomagnesemia (15% to 30%.), Hypophosphatemia (8% to 26%)<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis (1% to 5%)<\/li><li><b>Hematologic:<\/b>Pancytopenia (less than 1%)<\/li><li><b>Neurologic:<\/b>Seizure (10%)<\/li><li><b>Renal:<\/b>Acute renal failure (1% to 5%), Renal impairment (12% when patient is hydrated), Serum creatinine raised, Tubular necrosis, acute<\/li><\/ul>"},"6":{"id":"54kgs6","title":"Drug Name Info","sub":{"0":{"id":"54kgs6b17","title":"US Trade Names","mono":"Foscavir<br\/>"},"2":{"id":"54kgs6b19","title":"Class","mono":"<ul><li>Antiviral<\/li><li>Pyrophosphate Analog<\/li><li>Viral DNA Polymerase Inhibitor<\/li><\/ul>"},"3":{"id":"54kgs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"54kgs6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"54kgs7","title":"Mechanism Of Action","mono":"Foscarnet sodium selectively inhibits pyrophosphate binding on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases.<br\/>"},"8":{"id":"54kgs8","title":"Pharmacokinetics","sub":{"1":{"id":"54kgs8b24","title":"Distribution","mono":"<ul><li>Vd: 0.41 L\/kg to 0.52 L\/kg<\/li><li>Protein binding: 14% to 17%<\/li><\/ul>"},"3":{"id":"54kgs8b26","title":"Excretion","mono":"<ul><li>Renal clearance: 5.6 to 6.4 L\/hr<\/li><li>Dialyzable: Not evaluated (hemodialysis)<\/li><li>Total body clearance: 6.2 to 7.1 L\/hr<\/li><\/ul>"},"4":{"id":"54kgs8b27","title":"Elimination Half Life","mono":"3.3 to 4 hours (plasma); 87.5 hours (urinary excretion) <br\/>"}}},"9":{"id":"54kgs9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Use standard infusion pump for administration.<\/li><li>(infusion) Do not exceed the recommended infusion rate; use either a central venous line or peripheral vein catheter.<\/li><li>(peripheral line infusion) Dilute the 24 mg\/mL solution with D5W or NS to a concentration of 12 mg\/mL.<\/li><li>(central line infusion) No dilution is necessary.<\/li><li>Hydration therapy: 750 to 1000 mL of NS or D5W should be given prior to the first dose; for subsequent infusions, give 750 to 1000 mL of hydration fluid concurrently with 90 to 120 mg\/kg dose and 500 mL concurrently with 40 to 60 mg\/kg dose; administer hydration fluid concurrently with all doses of foscarnet after the first dose; decrease hydration fluid volume if clinically indicated; oral rehydration with similar regimens may be used.<\/li><\/ul>"},"10":{"id":"54kgs10","title":"Monitoring","mono":"<ul><li>Improvement of cytomegalovirus retinitis or herpes simplex virus infection; indicative of efficacy<\/li><li>Cytomegalovirus retinitis: Ophthalmologic examinations regularly during therapy<\/li><li>CrCl; at baseline and 2 to 3 times per week during induction therapy, and once weekly during maintenance therapy; determine 24-hour CrCl if necessary; and as clinically indicated<\/li><li>Electrolyte panel, including serum calcium, magnesium, potassium, and phosphorus; at baseline and 2 to 3 times per week during induction therapy, and once weekly during maintenance therapy and as clinically indicated<\/li><li>Signs and symptoms of electrolyte abnormalities<\/li><\/ul>"},"11":{"id":"54kgs11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Solution: 24 MG\/ML<br\/><\/li><li><b>Foscavir<\/b><br\/>Intravenous Solution: 24 MG\/ML<br\/><\/li><li><b>Novaplus Foscavir<\/b><br\/>Intravenous Solution: 24 MG\/ML<br\/><\/li><\/ul>"},"13":{"id":"54kgs13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to avoid driving, operating machinery, and other activities requiring coordination until drug effects are realized.<\/li><li>Patient should maintain adequate hydration to help prevent kidney damage during therapy.<\/li><li>This drug may cause diarrhea, nausea, vomiting, or headache.<\/li><li>Instruct patient to report signs\/symptoms of renal impairment or electrolyte abnormalities (perioral numbness, paresthesia, seizures).<\/li><\/ul>"}}}